Akito Nakamura

633 total citations
13 papers, 424 citations indexed

About

Akito Nakamura is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Akito Nakamura has authored 13 papers receiving a total of 424 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Organic Chemistry. Recurrent topics in Akito Nakamura's work include Melanoma and MAPK Pathways (5 papers), Computational Drug Discovery Methods (4 papers) and Synthesis and biological activity (3 papers). Akito Nakamura is often cited by papers focused on Melanoma and MAPK Pathways (5 papers), Computational Drug Discovery Methods (4 papers) and Synthesis and biological activity (3 papers). Akito Nakamura collaborates with scholars based in Japan, United States and Germany. Akito Nakamura's co-authors include Sei Yoshida, Takeo Arita, Masanori Okaniwa, Tomoyasu Ishikawa, Takahito Hara, Shunsuke Ebara, Akito Hata, Katherine Galvin, Jill Donelan and Elizabeth Carideo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.

In The Last Decade

Akito Nakamura

13 papers receiving 421 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Akito Nakamura Japan 8 326 119 63 60 58 13 424
Kazuhiro Ohara Japan 4 346 1.1× 138 1.2× 85 1.3× 53 0.9× 40 0.7× 6 407
Amy M. Delaney United States 7 292 0.9× 90 0.8× 54 0.9× 33 0.6× 56 1.0× 8 441
Sarah A Molton United States 7 436 1.3× 183 1.5× 69 1.1× 25 0.4× 48 0.8× 8 535
Martine B.W. Prinsen Netherlands 11 270 0.8× 151 1.3× 52 0.8× 29 0.5× 98 1.7× 19 456
Michael Grondine United States 8 421 1.3× 265 2.2× 50 0.8× 25 0.4× 76 1.3× 14 544
Deborah Moshinsky United States 11 270 0.8× 166 1.4× 24 0.4× 59 1.0× 31 0.5× 14 431
Yahao Bu United States 12 323 1.0× 146 1.2× 51 0.8× 16 0.3× 83 1.4× 16 515
Liv Johannessen United States 8 241 0.7× 152 1.3× 30 0.5× 30 0.5× 27 0.5× 19 374
Hélène Malka-Mahieu France 6 387 1.2× 136 1.1× 31 0.5× 21 0.3× 29 0.5× 10 456
Claire McWhirter United Kingdom 5 394 1.2× 79 0.7× 46 0.7× 20 0.3× 23 0.4× 8 478

Countries citing papers authored by Akito Nakamura

Since Specialization
Citations

This map shows the geographic impact of Akito Nakamura's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akito Nakamura with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akito Nakamura more than expected).

Fields of papers citing papers by Akito Nakamura

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akito Nakamura. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akito Nakamura. The network helps show where Akito Nakamura may publish in the future.

Co-authorship network of co-authors of Akito Nakamura

This figure shows the co-authorship network connecting the top 25 collaborators of Akito Nakamura. A scholar is included among the top collaborators of Akito Nakamura based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akito Nakamura. Akito Nakamura is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Nakamura, Akito, Stephen Grossman, Keli Song, et al.. (2022). The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation. Blood. 139(18). 2770–2781. 43 indexed citations
2.
Nakamura, Akito, Keli Song, Stephen Grossman, et al.. (2021). The Sumoylation Inhibitor TAK-981 in Combination with the CD19-Targeting Antibody Tafasitamab Shows Enhanced Anti-Tumor Activity in Preclinical B-Cell Lymphoma Models. Blood. 138(Supplement 1). 2268–2268. 1 indexed citations
3.
4.
Nakamura, Akito, Daisuke Nakata, Saomi Murai, et al.. (2018). CDK8/19 inhibition induces premature G1/S transition and ATR-dependent cell death in prostate cancer cells. Oncotarget. 9(17). 13474–13487. 31 indexed citations
5.
Nakamura, Akito, Tadahiro Nambu, Shunsuke Ebara, et al.. (2018). Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response. Proceedings of the National Academy of Sciences. 115(33). E7776–E7785. 110 indexed citations
6.
Nakamura, Akito & Hiromichi Kimura. (2017). A new role of GCN2 in the nucleolus. Biochemical and Biophysical Research Communications. 485(2). 484–491. 13 indexed citations
7.
Nakamura, Akito, Takeo Arita, Jill Donelan, et al.. (2013). Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma. Cancer Research. 73(23). 7043–7055. 92 indexed citations
8.
Okaniwa, Masanori, Masaaki Hirose, Takeo Arita, et al.. (2013). Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives. Journal of Medicinal Chemistry. 56(16). 6478–6494. 90 indexed citations
9.
Zhang, Julie, Jerome T. Mettetal, Kazuhide Nakamura, et al.. (2013). Use of combination treatment with the investigational RAF kinase inhibitor MLN2480 and the investigational MEK kinase inhibitor TAK-733 on the growth of BRAF-mutant and RAS-mutant preclinical models of melanoma and CRC.. Journal of Clinical Oncology. 31(15_suppl). e13529–e13529. 1 indexed citations
10.
11.
Okaniwa, Masanori, Masaaki Hirose, Takeo Arita, et al.. (2013). Abstract C255: Discovery of TAK-632: A selective kinase inhibitor of pan-RAF with potent antitumor activity against BRAF and NRAS mutant melanomas.. Molecular Cancer Therapeutics. 12(11_Supplement). C255–C255. 1 indexed citations
12.
Yamada, Tadaaki, Shinji Takeuchi, Naoya Fujita, et al.. (2012). Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. Oncogene. 32(37). 4427–4435. 24 indexed citations
13.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kazuhiro Ohara Breakdown of academic impact, for papers by Amy M. Delaney Breakdown of academic impact, for papers by Sarah A Molton Breakdown of academic impact, for papers by Martine B.W. Prinsen Breakdown of academic impact, for papers by Michael Grondine Breakdown of academic impact, for papers by Deborah Moshinsky Breakdown of academic impact, for papers by Yahao Bu Breakdown of academic impact, for papers by Liv Johannessen Breakdown of academic impact, for papers by Hélène Malka-Mahieu Breakdown of academic impact, for papers by Claire McWhirter
Rankless by CCL
2026